Cargando…
The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
The Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant formulated in a stable emulsion (GLA-SE) promotes strong T(H)1 and balanced IgG1/IgG2 responses to protein vaccine antigens. This enhanced immunity is sufficient to provide protection against many diseases including tuberculosis and leis...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701231/ https://www.ncbi.nlm.nih.gov/pubmed/26731269 http://dx.doi.org/10.1371/journal.pone.0146372 |
_version_ | 1782408440584339456 |
---|---|
author | Cauwelaert, Natasha Dubois Desbien, Anthony L. Hudson, Thomas E. Pine, Samuel O. Reed, Steven G. Coler, Rhea N. Orr, Mark T. |
author_facet | Cauwelaert, Natasha Dubois Desbien, Anthony L. Hudson, Thomas E. Pine, Samuel O. Reed, Steven G. Coler, Rhea N. Orr, Mark T. |
author_sort | Cauwelaert, Natasha Dubois |
collection | PubMed |
description | The Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant formulated in a stable emulsion (GLA-SE) promotes strong T(H)1 and balanced IgG1/IgG2 responses to protein vaccine antigens. This enhanced immunity is sufficient to provide protection against many diseases including tuberculosis and leishmaniasis. To better characterize the adjuvant action it is important to understand how the different cytokines and transcription factors contribute to the initiation of immunity. In the present study using T-bet(-/-) and IL-12(-/-) mice and a blocking anti-IFNαR1 monoclonal antibody, we define mechanisms of adjuvant activity of GLA-SE. In accordance with previous studies of TLR4 agonist based adjuvants, we found that T(H)1 induction via GLA-SE was completely dependent upon T-bet, a key transcription factor for IFNγ production and T(H)1 differentiation. Consistent with this, deficiency of IL-12, a cytokine canonical to T(H)1 induction, ablated T(H)1 induction via GLA-SE. Finally we demonstrate that the innate immune response to GLA-SE, including rapid IFNγ production by memory CD8+ T cells and NK cells, was contingent on type I interferon, a cytokine group whose association with T(H)1 induction is contextual, and that they contributed to the adjuvant activity of GLA-SE. |
format | Online Article Text |
id | pubmed-4701231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-47012312016-01-15 The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction Cauwelaert, Natasha Dubois Desbien, Anthony L. Hudson, Thomas E. Pine, Samuel O. Reed, Steven G. Coler, Rhea N. Orr, Mark T. PLoS One Research Article The Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant formulated in a stable emulsion (GLA-SE) promotes strong T(H)1 and balanced IgG1/IgG2 responses to protein vaccine antigens. This enhanced immunity is sufficient to provide protection against many diseases including tuberculosis and leishmaniasis. To better characterize the adjuvant action it is important to understand how the different cytokines and transcription factors contribute to the initiation of immunity. In the present study using T-bet(-/-) and IL-12(-/-) mice and a blocking anti-IFNαR1 monoclonal antibody, we define mechanisms of adjuvant activity of GLA-SE. In accordance with previous studies of TLR4 agonist based adjuvants, we found that T(H)1 induction via GLA-SE was completely dependent upon T-bet, a key transcription factor for IFNγ production and T(H)1 differentiation. Consistent with this, deficiency of IL-12, a cytokine canonical to T(H)1 induction, ablated T(H)1 induction via GLA-SE. Finally we demonstrate that the innate immune response to GLA-SE, including rapid IFNγ production by memory CD8+ T cells and NK cells, was contingent on type I interferon, a cytokine group whose association with T(H)1 induction is contextual, and that they contributed to the adjuvant activity of GLA-SE. Public Library of Science 2016-01-05 /pmc/articles/PMC4701231/ /pubmed/26731269 http://dx.doi.org/10.1371/journal.pone.0146372 Text en © 2016 Cauwelaert et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited |
spellingShingle | Research Article Cauwelaert, Natasha Dubois Desbien, Anthony L. Hudson, Thomas E. Pine, Samuel O. Reed, Steven G. Coler, Rhea N. Orr, Mark T. The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction |
title | The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction |
title_full | The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction |
title_fullStr | The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction |
title_full_unstemmed | The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction |
title_short | The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction |
title_sort | tlr4 agonist vaccine adjuvant, gla-se, requires canonical and atypical mechanisms of action for t(h)1 induction |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701231/ https://www.ncbi.nlm.nih.gov/pubmed/26731269 http://dx.doi.org/10.1371/journal.pone.0146372 |
work_keys_str_mv | AT cauwelaertnatashadubois thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT desbienanthonyl thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT hudsonthomase thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT pinesamuelo thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT reedsteveng thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT colerrhean thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT orrmarkt thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT cauwelaertnatashadubois tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT desbienanthonyl tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT hudsonthomase tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT pinesamuelo tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT reedsteveng tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT colerrhean tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction AT orrmarkt tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction |